The Japanese firm Olympus and Cytosurge have, according to a press release, agreed a marketing partnership. Their aim is to market an end-to-end solution for single cell and CRISPR gene manipulation in the Americas. To this end, a special microscope developed by Olympus will be used together with Cytosurge’s high-precision cell manipulation technology.
The two companies have identified a growing need in the world of science for next-generation single cell and CRISPR gene manipulation scenarios. The technology is of crucial significance in the understanding of the biological mechanisms of diseases. Thanks to this collaboration, the partners are empowering “researchers in both academia and the private sector to go beyond current technological barriers and help them bring new, much-needed therapies and medications to the market faster”, comments Pascal Behr, CEO of Cytosurge, in the press release.
Cytosurge is a spin-off from the Swiss Federal Institute of Technology in Zurich (ETH) and is headquartered in the Greater Zurich Area. The company has developed various nanotechnology solutions for single cell research, among other things. Cytosurge had actually already agreed a research partnership with Olympus last summer, the aim of which was to develop new instruments for single cell experiments.
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space